Literature DB >> 963850

Regional contractility. Selective depression of ischemic myocardium by verapamil.

H J Smith, R A Goldstein, J M Griffith, K M Kent, S E Epstein.   

Abstract

The effects of verapamil (0.02-0.2 mg/kg) on contractility in normal and partially ischemic myocardium were compared with the changes following propranolol (0.01-1.0 mg/kg). Regional contractile function was studied in open-chest dogs with ultrasonic crystals and ischemia was controlled by graded occlusion of a carotid-to-coronary artery shunt. Reduction in shunt perfusion pressure (40-55 mm Hg) resulted in hypokinesia. Verapamil depressed contractility in ischemic myocardium in 5/5 dogs, but did not alter the maximum velocity of shortening (max V) or end-diastolic segment length in normal myocardium. Propranolol in doses sufficient to depress ischemic myocardium also depressed contractile function in normal myocardium. In two dogs without coronary occlusion, verapamil (up to 1.0 mg/kg) increased end-diastolic segment length but did not reduce max V. We conclude that verapamil selectively depresses ischemic myocardium, a finding that may have clinical implication since ischemic injury can be decreased by reducing contractility (and thereby MVO2).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 963850     DOI: 10.1161/01.cir.54.4.629

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

Review 1.  Pharmacology of acute effort angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

Review 2.  The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

Authors:  W G Nayler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 4.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

5.  [3H]-verapamil binding to rat cardiac sarcolemmal membrane fragments; an effect of ischaemia.

Authors:  J S Dillon; W G Nayler
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

6.  Comparative investigation of the effects of metoprolol, propranolol, practolol, and verapamil in the acute phase of experimental myocardial infarction.

Authors:  W Bernauer
Journal:  Klin Wochenschr       Date:  1982-01-15

7.  Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries.

Authors:  K Bian; K Hermsmeyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

Review 8.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

9.  Influence of verapamil on cellular integrity and electrolyte concentrations of ischemic myocardial tissue in the cat.

Authors:  A M Lefer; E W Polansky; C P Bianchi; S Narayan
Journal:  Basic Res Cardiol       Date:  1979 Sep-Oct       Impact factor: 17.165

10.  The Ca2+ -antagonist and binding properties of the phenylalkylamine, anipamil.

Authors:  J S Dillon; W G Nayler
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.